本页面由Tiger Trade Technology Pte. Ltd.提供服务

Immunovant, Inc.

39.41
+0.04000.10%
盘后39.410.00000.00%19:34 EDT
成交量:72.71万
成交额:2,862.00万
市值:80.91亿
市盈率:-14.22
高:39.87
开:39.80
低:38.70
收:39.37
52周最高:41.23
52周最低:14.32
股本:2.05亿
流通股本:7,983.12万
量比:0.82
换手率:0.91%
股息:- -
股息率:- -
每股收益(TTM):-2.7716
每股收益(LYR):-2.7716
净资产收益率:-64.82%
总资产收益率:-38.43%
市净率:9.49
市盈率(LYR):-14.22

数据加载中...

公司资料

公司名字:
Immunovant, Inc.
交易所:
NASDAQ
成立时间:
2018
员工人数:
315
公司地址:
1000 Park Forty Plaza,Suite 210,Durham,North Carolina,United States
邮编:
27713
电话:
传真:
- -
简介:
Immunovant, Inc.于2018年12月6日在特拉华州注册成立,是一家临床阶段的免疫学企业,专注于开发自身免疫性疾病的治疗方法。主要推进FCRN抑制剂IMVT-1402靶向由致病性IgG抗体引发的自身免疫性疾病,此前还开发了另一种抗FCRN抗体batoclimab。该公司对其主要候选药物进行跨越内分泌学、神经病学、风湿病学和皮肤病学等多个疾病领域的临床研究,与HanAll合作设计高效抗-FCRN抗体,并已停止batoclimab的进一步开发以全面专注于IMVT-1402的临床进展,将batoclimab项目的试验运营经验和临床见解应用于其核心产品开发。

董事

名称
职位
Eric Venker
Chief Executive Officer and Director
Andrew Fromkin
Independent Director
Atul Pande
Independent Director
Douglas Hughes
Independent Director
Frank M. Torti
Director and Executive Chairperson of the Board
Jacob Bauer
Independent Director
Robert Susman
Independent Director

股东

名称
职位
Eric Venker
Chief Executive Officer and Director
Melanie Gloria
Chief Operating Officer
Tiago Girão
Chief Financial Officer
Christopher Van Tuyl
Chief Legal Officer and Corporate Secretary
Frank M. Torti
Director and Executive Chairperson of the Board
Jay S. Stout
Chief Technology Officer